文章基本信息

标题：Resistance to direct antiviral agents for hepatitis C virus infection. Impact on clinical practice?
本地全文：下载
作者：Ana Belén Pérez ; Federico García
期刊名称：Germs
印刷版ISSN：2248-2997
出版年度：2016
卷号：6
期号：4
页码：123
出版社：European HIV/AIDS and Infectious Diseases Academy
摘要：Since the first generation protease inhibitors boceprevir & telaprevir were approved in combination therapy with peginterferon & ribavirin, we live in a time of outstanding revolution in hepatitis C virus infection. For many of us, this may be the first opportunity to see how an infectious disease agent was discovered and, also, how it may be eradicated. The opportunity to cure HCV infection became real when HCV life cycle was described, and viral targets for HCV direct antiviral agents (DAA) were identified. Protease inhibitors, first, followed by the high genetic barrier NS5B inhibitor sofosbuvir and the highly potent NS5A inhibitors, used in combination, have made possible to achieve cure rates that only 5 years ago were unthinkable. Today, different HCV genotypes can be treated with